drugset / Trial / NCT04952857

Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease

NCT04952857

RandomizedParallel-groupDouble-blindTreatment

Summary

COVID-19 caused by SARS-CoV-2 virus has affected the lives of millions of individuals globally and also severely strained the medical community. Pre-symptomatic and asymptomatic SARS-CoV-2 positive individuals far outnumber the symptomatic ones or those with severe disease. The transmission potential of SARS CoV-2 is potentially greater than earlier viral outbreaks of SARS-CoV and MERS-CoV.Routine measures of social distancing, personal hand hygiene and limited outdoor contact activities have shown benefits to limit corona virus infection. However, the role of vitamin D in SARS-CoV-2 infection is sparingly explored despite the knowledge of an immunomodulatory role and protective effect of vitamin D against viral infections. Meta-analysis of five clinical trials of vitamin D supplementation found that those receiving vitamin D supplementation had fewer respiratory tract infections (odds ratio = 0.58 (95%CI, 0.42 - 0.81).Any immune-modulatory effect of vitamin D is likely to be observed at levels which are considered higher than that required for normal bone metabolism.

Timeline

Start
2021-08-01
Primary completion
2021-11-30
Completion
2021-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 600000 iu Oral

Indications